Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia

This study has been terminated.
(Low Recruitment)
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01204788
First received: September 15, 2010
Last updated: March 5, 2013
Last verified: March 2013
  Purpose

Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk for infection. The standard of care for preventing infections is to give these patients antibiotic, antifungal, and antiviral drugs during the time that white blood cell counts are low. However, many patients still develop infections during chemotherapy. Radiated white blood cell transfusions are a standard treatment once a patient develops a severe infection.

The goal of this clinical research study is to learn if giving unirradiated white blood cell transfusions early in chemotherapy might delay or prevent infections in patients with leukemia. Researchers also want to learn more about the type and severity of any infections that do occur.


Condition Intervention Phase
Leukemia
Procedure: Prophylactic White Cell Transfusion
Procedure: Therapeutic White Cell Transfusion
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Prospective Randomized Comparative Study of the Effect on Infections of Radiated Prophylactic White Cell Transfusions Versus Therapeutic Radiated White Cell Transfusions

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Number of Patients with Infection [ Time Frame: Blood draw 2-3 times a week while hospitalized, weekly thereafter. Patient will remain on study 42 days after transfusion. ] [ Designated as safety issue: No ]
    Primary outcome is infection (yes/no) where patient without infection found by day 42 patient are counted as 'No' to infection.


Enrollment: 5
Study Start Date: September 2010
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 (Prophylactic Arm)
Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
Procedure: Prophylactic White Cell Transfusion
Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
Experimental: Arm 2 (Therapeutic Arm)
Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
Procedure: Therapeutic White Cell Transfusion
Radiated white blood cell transfusions daily only with infection (or persistent fever)

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult and pediatric (=/> 2 years old) patients with a diagnosis of acute myelogenous leukemia (including undifferentiated and bi-phenotypic leukemia), or high-risk myelodysplastic syndrome, or chronic myelogenous leukemia in blast crisis who will receive first or second anti-leukemia therapeutic intent with chemotherapy, targeted therapy or hypomethylating agents
  2. Patients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital.

Exclusion Criteria:

  1. Patients with baseline (at start leukemia treatment) infection, defined as patients with a)fever and known positive cultures at the time of randomization; or b) chest or sinus computed tomography with findings suggestive of pneumonia or sinusitis; or c) one positive galactomannan test >/= 1 or two positive galactomannan text >/= 0.5 to 1
  2. Patients with Zubrod performance status >/= 3
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01204788

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Emil J Freireich, MD, BS UT MD Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01204788     History of Changes
Other Study ID Numbers: 2010-0468
Study First Received: September 15, 2010
Last Updated: March 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Acute myelogenous leukemia
AML
Undifferentiated and bi-phenotypic leukemia
High-risk myelodysplastic syndrome
Chronic myelogenous leukemia
Infection
Radiated Prophylactic White Cell Transfusions
Therapeutic Radiated White Cell Transfusion
prophylactic antibiotics

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014